Venture Life drives revenue growth through brand expansion and AI-powered digital strategy (VLG)

Venture Life (LSE:VLG) delivered revenue of £50.0 million for the 17 months to 31 May 2026, representing a 30.9% increase on the previous reporting period, while pro forma revenue grew 16.0%, driven primarily by higher sales volumes. The company’s Power Brands now generate more than 90% of total revenue, with products including Lift, Balance Activ and Earol recording strong performances following increased marketing investment, new product launches and renewed partnerships with international distributors. Adjusted EBITDA is expected to be in line with market expectations.

AI transformation underpins operational strategy

Venture Life is implementing a digital-first transformation programme centred on Microsoft Dynamics 365, using artificial intelligence to improve demand forecasting, promotional planning and stock-keeping unit management. The company expects the initiative to deliver measurable financial benefits within the next 12 months. Net cash declined to approximately £12.0 million following the acquisitions of FemiClear and CUROXEN, while adjusted free cash flow improved to around £5.9 million. Management believes the group’s balance sheet remains strong enough to support further investment in brand marketing, portfolio optimisation and earnings-accretive acquisitions across its core UK and US markets.

Outlook

Venture Life’s outlook is supported by improving profitability and a significantly strengthened balance sheet with very low debt levels. However, these positives are partly offset by the swing to negative operating and free cash flow during 2025, together with fluctuating revenue and margin performance. Technical indicators remain weak despite oversold conditions, while valuation remains difficult to assess because of the company’s negative price-to-earnings ratio and the absence of a stated dividend yield.

More about Venture Life

Venture Life Group PLC is a UK-listed consumer healthcare company specialising in the innovation, development and commercialisation of products across women’s intimate health, ear care, energy, glucose management and menopause support. Its portfolio of Power Brands includes Balance Activ, Lift, Glucogel, Earol, Health & Her and Health & Him, alongside a growing oncology support range featuring Gelclair and Pomi-T. The company continues to focus its commercial expansion on the UK and US markets.